These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25238700)

  • 21. Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure.
    Hu CD; Choo R; Huang J
    Front Oncol; 2015; 5():90. PubMed ID: 25927031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular aspects of prostate cancer with neuroendocrine differentiation.
    Li Q; Zhang CS; Zhang Y
    Chin J Cancer Res; 2016 Feb; 28(1):122-9. PubMed ID: 27041934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer.
    Nordin A; Wang W; Welén K; Damber JE
    Prostate; 2013 May; 73(6):657-67. PubMed ID: 23129424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.
    Berruti A; Bollito E; Cracco CM; Volante M; Ciccone G; Porpiglia F; Papotti M; Scarpa RM; Dogliotti L
    Prostate; 2010 May; 70(7):718-26. PubMed ID: 20087896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of neuroendocrine differentiation in castration resistant prostate cancer cells by adipocyte differentiation-related protein (ADRP) delivered by exosomes.
    Lin LC; Gao AC; Lai CH; Hsieh JT; Lin H
    Cancer Lett; 2017 Apr; 391():74-82. PubMed ID: 28109910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting PKLR/MYCN/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer.
    Chen WY; Thuy Dung PV; Yeh HL; Chen WH; Jiang KC; Li HR; Chen ZQ; Hsiao M; Huang J; Wen YC; Liu YN
    Redox Biol; 2023 Jun; 62():102686. PubMed ID: 36963289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pyruvate kinase L/R links metabolism dysfunction to neuroendocrine differentiation of prostate cancer by ZBTB10 deficiency.
    Wen YC; Chen WY; Tram VTN; Yeh HL; Chen WH; Jiang KC; Abou-Kheir W; Huang J; Hsiao M; Liu YN
    Cell Death Dis; 2022 Mar; 13(3):252. PubMed ID: 35306527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
    Yuan TC; Veeramani S; Lin FF; Kondrikou D; Zelivianski S; Igawa T; Karan D; Batra SK; Lin MF
    Endocr Relat Cancer; 2006 Mar; 13(1):151-67. PubMed ID: 16601285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroendocrine differentiation is involved in chemoresistance induced by EGF in prostate cancer cells.
    Li Y; Chen HQ; Chen MF; Liu HZ; Dai YQ; Lv H; Bing Zu X; Qi L
    Life Sci; 2009 Jun; 84(25-26):882-7. PubMed ID: 19356736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
    Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
    Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
    Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
    Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
    Alberti C
    G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective study on the relationship between clinical efficacy of secondary hormone therapy with flutamide and neuroendocrine differentiation in patients with relapsed prostate cancer after first line hormone therapy.
    Hirano D; Hasegawa R; Satoh K; Mochida J; Yamanaka Y; Hirakata H; Yamaguchi K; Sugimoto S; Kawata N; Takahashi S
    Scand J Urol; 2014 Oct; 48(5):436-44. PubMed ID: 24730473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.
    Yuan TC; Veeramani S; Lin MF
    Endocr Relat Cancer; 2007 Sep; 14(3):531-47. PubMed ID: 17914087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of neuroendocrine differentiation in patients with Gleason score 8-10 prostate cancer treated with primary radiotherapy.
    Krauss DJ; Hayek S; Amin M; Ye H; Kestin LL; Zadora S; Vicini FA; Cotant M; Brabbins DS; Ghilezan MI; Gustafson GS; Martinez AA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e119-25. PubMed ID: 21596486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Does neuroendocrine differentiation have prognostic value in prostate core needle biopsies?].
    Jaskulski J; Gołabek T; Kopczyński J; Orłowsk P; Bukowczan J; Dudek P; Chłosta P
    Przegl Lek; 2013; 70(11):933-5. PubMed ID: 24697032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting CREB inhibits radiation-induced neuroendocrine differentiation and increases radiation-induced cell death in prostate cancer cells.
    Suarez CD; Deng X; Hu CD
    Am J Cancer Res; 2014; 4(6):850-61. PubMed ID: 25520873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Large-cell neuroendocrine carcinoma of prostate. Case report.
    Moratalla Charcos LM; Pastor Navarro T; Cortes Vizcaino V; Osca Garcia JM; Gil Salom M
    Arch Esp Urol; 2013 May; 66(4):368-71. PubMed ID: 23676541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors in prostate cancer.
    Stattin P
    Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.